In Section C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Individuals will receive treatment until illness progression or even the individuals are unable to tolerate the study drugs. 88 These preclinical studies give paradigms for potential clinical trials in AML, and https://abbv-744inclinicaltrialsf80246.azzablog.com/32217579/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing